Читать книгу The SAGE Encyclopedia of Stem Cell Research - Группа авторов - Страница 418
The use of escalating doses of selective inhibitor of nuclear export (KPT-330) in patients with advanced hematological cancers
ОглавлениеA new phase I clinical trial aims to investigate the pharmacokinetics (how the body affects the concentrations of the drug in the blood) and pharmacodynamics (the effect of the drug on the body) of this small molecule inhibitor of nuclear export. The study will help determine the highest dose of KPT-330 that can be given safely and the side effects it may cause.
The study will also help to understand occurrence of adverse events, severity of the adverse events, and area under the plasma concentration versus time curve (AUC) of KPT-330, which will determine the change in AUC over time.
